EMPLOYMENT AGREEMENTEmployment Agreement • March 17th, 2008 • Omrix Biopharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMarch 17th, 2008 Company Industry JurisdictionEMPLOYMENT AGREEMENT (the “Agreement”) dated August 24, 2007 by and between Omrix Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and V. Marc Droppert (the “Executive”).
LEASE RCPI LANDMARK PROPERTIES, L.L.C., a Delaware limited liability company Landlord and OMRIX BIOPHARMACEUTICALS INC., a Delaware corporation Tenant for Rockefeller Center 630 Fifth Avenue New York, New York September 19, 2006Lease • March 17th, 2008 • Omrix Biopharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 17th, 2008 Company Industry JurisdictionTHIS LEASE is made as of the ___ day of ___, 2006 (“Effective Date”), between RCPI LANDMARK PROPERTIES, L.L.C. (“Landlord”), a Delaware limited liability company, and OMRIX BIOPHARMACEUTICALS INC. (“Tenant”), a Delaware corporation.
FIRST AMENDMENT TO LEASELease • March 17th, 2008 • Omrix Biopharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 17th, 2008 Company Industry JurisdictionThis FIRST AMENDMENT TO LEASE dated as of March 12, 2007 (this “Amendment”) between RCPI LANDMARK PROPERTIES, L.L.C., a Delaware limited liability company having an office c/o Tishman Speyer Properties, L.P., 45 Rockefeller Plaza, New York, New York 10111 (“Landlord”), and OMRIX BIOPHARMACEUTICALS INC., a Delaware corporation having an office at 630 Fifth Avenue, 22nd Floor, New York, New York 10111 (“Tenant”).
Amendment to Construction Agreement Of March 13, 2008Amendment to Construction Agreement • March 17th, 2008 • Omrix Biopharmaceuticals, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 17th, 2008 Company IndustryBetween: Omrix Biopharmaceuticals Ltd. Company No. 512166059 Of Blood Services Building, P.O. Box 888 Tel Hashomer, Kiryat Ono, 55100 (hereinafter: the “Customer”)